Kyverna Therapeutics Inc. (KYTX) Live Share Price, Invest From India

Kyverna Therapeutics Inc. Stock Performance

as on July 14, 2026 at 2:16 pm IST

Day's Low
Day's High
$7.70
Day's Price Range
$8.39
$7.77
0.90%
Downside
7.98%
Upside
52 Week's Low
52 Week's High
$2.80
52-Week Price Range
$13.67
$7.77
63.96%
Downside
75.93%
Upside

Kyverna Therapeutics Inc. share price movements today

Previous Close: $8.48
Open: $8.37
Volume: 2.0M
Day's Low - High: $7.70 - $8.39
52 Week Low - High: $2.80 - $13.67

Kyverna Therapeutics Inc. Historical Returns

1 Month Return: -3.54 %
3 Month Return: -16.99 %
1 Year Return: + 76.79 %
3 Year Return: 0 %
5 Year Return: 0 %

Kyverna Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Kyverna Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$515.8M

EPS (TTM)

-2.8772

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-162.1M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-74.55%

Kyverna Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kyverna Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Kyverna Therapeutics Inc.	BUY	$515.8M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$39.9B	69.11%	75.25	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$123.2B	142.69%	28.82	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$69.7B	14.12%	16.24	29.65%	0.54%

Stock Returns calculator for Kyverna Therapeutics Inc. Stock including INR - Dollar returns

The Kyverna Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Kyverna Therapeutics Inc. investment value today

Current value as on today

₹1,96,744

Returns

₹96,744

(+96.74%)

Returns from Kyverna Therapeutics Inc. Stock

₹76,993 (+76.99%)

Dollar Impact

₹19,751 (+19.75%)

Analyst Recommendation on Kyverna Therapeutics Inc. Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Kyverna Therapeutics Inc.. Average target price of $30.4

Kyverna Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Kyverna Therapeutics Inc..

What analysts predicted

74.44%UPSIDE

Target Price

$30.4

Current Price

$7.77

Analyzed by

10 Analysts

Target

$30.40

Kyverna Therapeutics Inc. target price $30.4, a slight upside of 74.44% compared to current price of $7.77. According to 10 analysts rating.

Indian Investors' Interest in Kyverna Therapeutics Inc. Stock

Search interest for Kyverna Therapeutics Inc. Stock has decreased by -39% in the last 30 days, reflecting a downward trend in search activity.

Time period: June 14, 2026 to July 14, 2026

Change:-39% versus previous 30 day period

Kyverna Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	2	-	-	-	-	-
Gross Profit	-17	0	0	-29	0	0	0	0	0	0
Operating Income	-21	0	-33	-38	-41	-47	-44	-38	-39	-41
EBITDA	-20	0	-28	-36	-36	-44	-41	-36	-36	-38
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-20	0	-28	-34	-37	-44	-42	-36	-37	-39
Income Tax Expense	0	0	-	-	-	-	-	-	-	-
Net Income	-20	0	-28	-34	-37	-44	-42	-36	-37	-39
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-1852.22%	0.00%	0.00%	0.00%	0.00%	0.00%

Kyverna Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	5	7	-	-	-
Gross Profit	5	7	-1	-2	-1
Operating Income	-26	-29	-62	-142	-169
EBITDA	-25	-27	-58	-125	-159
Interest Expense	0	0	0	0	0
Depreciation	0	1	1	2	1
Income Before Tax	-26	-28	-60	-127	-161
Income Tax Expense	0	0	0	-127	-
Net Income	-26	-28	-60	-127	-161
Net Profit Margin	-465.88%	-411.29%	0.00%	0.00%	0.00%

Kyverna Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-26	-28	-34	-37	-44	-42	-36	-37	-39
Operating Cash Flow	-25	-24	-27	-37	-44	-31	-43	-33	-41
Investing Cash Flow	-122	-67	0	29	5	29	22	-17	-50
Financing Cash Flow	338	0	0	0	0	0	1	140	0
Change in Cash	189	-92	-26	-8	-39	-3	-19	89	-91

Kyverna Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-28	-60	-127	-161
Operating Cash Flow	-36	-52	-114	-153
Investing Cash Flow	-14	-8	-160	40
Financing Cash Flow	11	58	337	141
Change in Cash	-38	-3	61	27

Global Institutional Holdings in Kyverna Therapeutics Inc.

Funds	Holdings
Woodline Partners LP	1.4%
Propel Bio Management LLC	1.1%
INSIGHT HOLDINGS GROUP, LLC	1.63%
Deerfield Management Co	3.3%
Vanguard Capital Management, LLC	2.95%

See all

Insights on Kyverna Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, KYTX has outperformed top 5 stocks with highest market-cap in its industry
NEGATIVE IMPACT
Price Dip
In the last 7 days, KYTX stock has moved down by -12.3%

About Kyverna Therapeutics Inc.

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Organisation	Kyverna Therapeutics Inc.
Headquarters	5980 Horton Street, EmeryVille, CA, United States, 94608
Industry	Biotechnology
CEO	Mr. Warner Biddle
E-voting on shares	Click here to vote

Key Management of Kyverna Therapeutics Inc.

Name	Title
Mr. Warner Biddle	CEO & Director
Mr. Gregory Martini	Chief Financial Officer
Dr. Tom Van Blarcom Ph.D.	Senior VP & Head of Research
Ms. Jessica Serra	Head of Investor Relations
Mr. Ritesh Srivastava	Chief Legal & Compliance Officer
Ms. Christi L. Shaw	Executive Chairperson
Dr. Marc Grasso M.D.	Strategic Advisor
Mr. Mayo Pujols	Chief Technology Officer
Ms. Cara Bauer Ph.D.	Chief Human Resources Officer
Dr. Naji H. Gehchan M.B.A., M.D.	Chief Medical & Development Officer

FAQs

What is Kyverna Therapeutics Inc. share price today?

Kyverna Therapeutics Inc. share price today is $7.77 as on July 14, 2026 at 8:46 am IST at the close of the market. Kyverna Therapeutics Inc. share today touched a day high of $8.39 and a low of $7.70.

What is the 52 week high and 52 week low for Kyverna Therapeutics Inc. share?

Kyverna Therapeutics Inc. share touched a 52 week high of $13.67 on December 15, 2025 and a 52 week low of $2.80 on August 12, 2025. Kyverna Therapeutics Inc. stock price today i.e. July 14, 2026 at 8:46 am IST is closed at $7.77,which is 43.16% down from its 52 week high and 177.50% up from its 52 week low.

What is Kyverna Therapeutics Inc.'s market capitalisation today?

Kyverna Therapeutics Inc. market capitalisation is $0.00T as on July 14, 2026 at 8:46 am IST.

How to invest in Kyverna Therapeutics Inc. Stock (KYTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Kyverna Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kyverna Therapeutics Inc. Shares that will get you 0.1931 shares as per Kyverna Therapeutics Inc. share price of $7.77 per share as on July 14, 2026 at 8:46 am IST.

What is the minimum amount required to buy Kyverna Therapeutics Inc. Stock (KYTX) from India?

Indian investors can start investing in Kyverna Therapeutics Inc. (KYTX) shares with as little as ₹95.615 or $1 (as of July 14, 2026 at 4:43 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹956.15 in Kyverna Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on July 14, 2026 at 4:43 pm IST). Based on Kyverna Therapeutics Inc. share’s latest price of $7.77 as on July 14, 2026 at 8:46 am IST, you will get 1.2870 shares of Kyverna Therapeutics Inc.. Learn more about fractional shares .